Nanodropper for Primary Open-Angle Glaucoma Treatment
Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial
Recruiting
N/A
Interventional Study
Ocular Hypertension
Primary Open Angle Glaucoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 30 (estimated)
- Sponsor
- 59th Medical Wing · Federal
Who this trial is looking for
This trial is looking for adults with primary open-angle glaucoma or ocular hypertension. Participants will compare a new way of applying eye drops to the standard method.
Are You a Good Fit for This Trial?
You may be able to join if
- I am over 18 years old.
- I have primary open-angle glaucoma or ocular hypertension.
- I am using a maximum of 2 medications to lower eye pressure.
- My eye condition has not changed in the last year.
You may not be able to join if
- I have a type of glaucoma other than primary open-angle glaucoma or ocular hypertension.
- My eye condition has progressed in the past year.
- I am using more than 2 medications to lower eye pressure.
- I have had eye surgery or laser treatment for lowering eye pressure within the last 6 months, except for SLT.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
This randomized, single-masked, crossover, non-inferiority trial aims to evaluate the safety and efficacy of Nanodropper-mediated microdrops of ocular hypotensive topical treatments (experimental intervention) compared to standard drops of the same medication(s) (active comparator) in Wilford Hall Ambulatory Surgical Center (WHASC) primary open-angle glaucoma (POAG) and ocular hypertension (OHTN) …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* POAG/OHTN patients above the age of 18 years.
* On a maximum of 2 IOP lowering medications.
* Stable disease without progression in IOP, optic disc cupping, RNFL changes, and visual field changes within the previous 1 year.
Exclusion Criteria:
* Glaucoma not of the POAG or O…
Contacts